IconICLR
ICLR
About: Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Employees: 41,250
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
7% more funds holding in top 10
Funds holding in top 10: 15 [Q3] → 16 (+1) [Q4]
1.51% less ownership
Funds ownership: 93.56% [Q3] → 92.05% (-1.51%) [Q4]
11% less funds holding
Funds holding: 653 [Q3] → 581 (-72) [Q4]
26% less repeat investments, than reductions
Existing positions increased: 184 | Existing positions reduced: 250
28% less capital invested
Capital invested by funds: $22.1B [Q3] → $15.9B (-$6.11B) [Q4]
42% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 152
66% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $96.4M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
12%
upside
Avg. target
$176
31%
upside
High target
$215
61%
upside
8 analyst ratings
3 positive
38%
5 neutral
63%
0 negative
0%
Barclays Luke Sergott 33% 1-year accuracy 21 / 63 met price target | 16%upside $155 | Equal-Weight Maintained | 2 May 2025 |
Goldman Sachs Matthew Sykes 43% 1-year accuracy 15 / 35 met price target | 20%upside $160 | Neutral Maintained | 2 May 2025 |
Baird Eric Coldwell 38% 1-year accuracy 3 / 8 met price target | 20%upside $160 | Neutral Maintained | 2 May 2025 |
JP Morgan Casey Woodring 0% 1-year accuracy 0 / 6 met price target | 12%upside $150 | Neutral Downgraded | 29 Apr 2025 |
TD Cowen Charles Rhyee 0% 1-year accuracy 0 / 3 met price target | 17%upside $157 | Hold Downgraded | 14 Apr 2025 |
Financial journalist opinion
Based on 12 articles about ICLR published over the past 30 days
Neutral
Business Wire
1 week ago
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the pote.
Neutral
PRNewsWire
1 week ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall LAW FIRM
LOS ANGELES , May 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
Seeking Alpha
1 week ago
ICON Public Limited Company (ICLR) Q1 2025 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q1 2025 Earnings Call Transcript May 1, 2025 8:00 AM ET Company Participants Kate Haven - Vice President, Investor Relations Steve Cutler - Chief Executive Officer Nigel Clerkin - Chief Financial Officer Barry Balfe - Chief Operating Officer Conference Call Participants Ahmed Muhammad - Leerink Partners Patrick Donnelly - Citi David Windley - Jefferies Justin Bowers - Deutsche Bank Jack Meehan - Nephron Research Jailendra Singh - Truist Securities Max Smock - William Blair Dan Leonard - UBS Michael Ryskin - Bank of America Luke Sergott - Barclays Matt Sykes - Goldman Sachs Eric Caldwell - Baird Charles Rhyee - TD Cowen Casey Woodring - JPMorgan Josh Waldman - Cleveland Research Operator Good day and thank you for standing by. Welcome to the ICON plc Q1 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
1 week ago
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.
Positive
Zacks Investment Research
1 week ago
Icon PLC (ICLR) Beats Q1 Earnings Estimates
Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago.
Neutral
Business Wire
1 week ago
ICON Reports First Quarter 2025 Results
DUBLIN--(BUSINESS WIRE)--ICON Reports First Quarter 2025 Results.
Neutral
Zacks Investment Research
2 weeks ago
What to Expect From These 3 MedTech Stocks This Earnings Season?
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
Neutral
PRNewsWire
2 weeks ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , April 29, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Neutral
PRNewsWire
2 weeks ago
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , April 24, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.
Negative
Zacks Investment Research
3 weeks ago
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™